{{Medical}}{{Infobox disease |
  Name           = 骨髓增生性疾病 |
  Image          = |
  Caption        = |
  ICD10          = {{ICD10|D|47|1|d|37}} |
  ICD9           = {{ICD9|205.1}}, {{ICD9|238.4}}, {{ICD9|289.89}}, {{ICD9|289.9}} |
  ICDO           = 9950/0-9964/3  |
  OMIM           = |
  DiseasesDB     = |
  MedlinePlus    = |
  eMedicineSubj  = |
  eMedicineTopic = |
  MeshID         = D009196 |
}}

'''骨髓增生性疾病'''（myeloproliferative diseases, MPDs）新名为'''骨髓增殖性肿瘤'''（myeloproliferative neoplasms, MPNs），是一类[[骨髓|骨髓]][[增生|增生]]过多[[血细胞|血细胞]]而形成的[[疾病|疾病]]。此类疾病与[[骨髓增生异常综合征|骨髓增生异常综合征]]或[[急性骨髓性白血病|急性骨髓性白血病]]有关或产生，尽管骨髓增生性疾病在与其他恶性血液疾病相比，有较良好预后。

1951年，血液学家{{link-en|威廉·达莫夏科|William Dameshek}}（{{lang|en|William Dameshek}}）首先提出了这一定义<ref>{{cite journal | author = Dameshek W | title = Some speculations on the myeloproliferative syndromes | journal = Blood | volume = 6 | issue = 4 | pages = 372–5 | year = 1951 | pmid = 14820991}}</ref>。在2008年世界卫生组织定义中，已改用新名<ref>{{Cite web|url=https://www.cancersupportcommunity.org/myeloproliferative-neoplasms|title=Myeloproliferative Neoplasms|website=Cancer Support Community}}</ref><ref name=Tefferi>{{cite journal |author=Tefferi A, Vainchenker W |title=Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies |journal=J. Clin. Oncol. |volume=29 |issue=5 |pages=573–82 |pmid=21220604 |doi=10.1200/JCO.2010.29.8711|date=February 2011}}2</ref>，这反映出此类疾病的主要原因是更深层的基因突变。

==分类==
尽管每一种恶性肿瘤都与其他癌症不同，骨髓增生性疾病仍然被视为{{link-en|恶性血液肿瘤|Hematological malignancy}}之列。有四类主要的骨髓增殖性肿瘤，其中主要分类以[[费城染色体|费城染色体]]的出现与否。

{| class="wikitable"
|-
! 费城染色体呈“阳性”
! 费城染色体呈“阴性”
|-
| 
* [[慢性粒细胞性白血病|慢性粒细胞性白血病]] (CML)
| 
* {{link-en|真性红细胞增多症|Polycythemia vera}} (PV)
* {{link-en|原发性血小板增多症|Essential thrombocytosis}} (ET)
* {{link-en|骨髓纤维化|Myelofibrosis}} (MF)
|-
|}

在2001年，[[世界卫生组织|世界卫生组织]]将“{{link-en|慢性嗜酸细胞白血病|chronic eosinophilic leukemia}}或[[嗜酸性粒细胞增多症|嗜酸性粒细胞增多症]]”和{{link-en|慢性中性粒细胞白血病|chronic neutrophilic leukemia}}归类为“慢性骨髓增殖性疾病”。<ref name="urlClassification of Human Hematopoietic Malignancies">{{cite web |url=http://emice.nci.nih.gov/emice/mouse_models/organ_models/hema_models/hema_human_class |title=Classification of Human Hematopoietic Malignancies |format= |work= |deadurl=yes |archiveurl=https://web.archive.org/web/20100527112518/http://emice.nci.nih.gov/emice/mouse_models/organ_models/hema_models/hema_human_class |archivedate=2010年5月27日 |df= }}</ref>

==病因==
所有的骨髓增生性疾病都因骨髓系统中前体淋巴细胞变异引起。这些淋巴细胞会产生一系列相似疾病，包括{{link-en|淋巴组织增殖性疾病|lymphoproliferative disorder}}（[[急性淋巴细胞白血病|急性淋巴细胞白血病]]、[[淋巴瘤|淋巴瘤]]、[[慢性粒细胞白血病|慢性粒细胞白血病]]和[[多发性骨髓瘤|多发性骨髓瘤]]）。

绝大多数原因均与一个激活的JAK2或MPL突变有关<ref name=Tefferi2011>{{cite journal |author=Tefferi A, Vainchenker W |title=Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies |journal=J. Clin. Oncol. |volume=29 |issue=5 |pages=573–82 |pmid=21220604 |doi=10.1200/JCO.2010.29.8711|date=February 2011}}</ref>。一个更小子集也包括一类突变，包括在LNK、CBL、TET2、ASXL1、IDH、IKZF1或EZH2基因组中。关于此类突变的病理研究仍在进行中。96%的{{link-en|真性红细胞增多症|Polycythemia vera}}患者均有一个在JAK2基因组第14外显子的V617F位置突变。<ref name=Passamonti2011>{{cite journal |author=Passamonti F, Maffioli M, Caramazza D, Cazzola M |title=Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies |journal=Oncotarget |volume=2 |issue=6 |pages=485–90 |pmid=21646683 |pmc=3248205|date=June 2011}}</ref>

== 诊断 ==
一类基于骨髓增生性疾病的特征而制定的诊断方法包括有：红细胞质量测定（针对红血球增多症）、骨髓穿刺、骨髓活检、动脉血氧饱和度、碳氧血红蛋白水平、嗜中性粒细胞碱性磷酸酶水平、[[维生素B|维生素B]]<sub>12</sub>结合力以及血清尿酸检查<ref>{{cite book |author=Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates |title=Dacie & Lewis Practical Haematology |publisher=W B Saunders |location=London |year= 2001|isbn=0-443-06377-X |page=586}}</ref>。

根据世界卫生组织造血和淋巴肿瘤的分类，骨髓增生性疾病分为依诊断特征分为以下几类：

===1. 慢性粒细胞性白血病===
两个染色体（[[9号染色体|9号染色体]]与[[22号染色体|22号染色体]]）发生易位，此导致在22号染色体的BCR基因与9号染色体的ABL基因相融合，有三种类型：
a. u-BCR-ABL (p230)：慢性粒细胞性白血病伴有中性细胞及嗜碱细胞增多<br>
b.  minor-BCR-ABL (p190)：慢性粒细胞性白血病有恶化倾向转移为急性骨髓性白血病（ALL），伴有急性骨髓性白血病前期症状<br>
c.  major-BCR-ABL (p210): 常规断点

===2. 原发性骨髓纤维化 (PMF)===
超过50%的患者均伴有{{link-en|JAK2基因|JAK2}}突变；超过5%的患者伴有MPL基因（血小板生成素受体）突变。<br>
a.  细胞期 -  巨核细胞增加伴有集群网状纤维化以及成熟期三色纤维，髓样前体细胞增加<br>
b.  纤维化期 - 胶原纤维，缺乏骨髓质

===3. 真性红细胞增多症 (PV)===
超过80%的患者伴有{{link-en|JAK2基因|JAK2}}突变<br>
a.  细胞期 - 巨核细胞增加伴有集群网状纤维化以及成熟期三色纤维，骨髓及红细胞前体细胞增加<br>
b.  纤维化期 - 胶原纤维，缺乏骨髓质

===4.  原发性血小板增多症 (ET)===
超过20%的患者均伴有{{link-en|JAK2基因|JAK2}}突变；超过15%的患者伴有MPL基因（血小板生成素受体）突变。<br>
a.  细胞期 - 巨核细胞增加伴有纤维化，在其他骨髓质中也有此类增加<br>
b.  纤维化期 - 胶原纤维，缺乏骨髓质

根据特殊的基因突变和病人的骨髓纤维化情况，这些诊断仍须作出针对性的修改调整。

在2005年，JAK2 V617F基因突变的发现，解释了一类常见的病理问题，即费城染色体呈阴性时的一类骨髓增生性疾病。<ref>{{cite journal | author = Baxter EJ, Scott LM, Campbell PJ, et al. | title = Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | journal = Lancet | volume = 365 | pages = 1054–1061 | year = 2005 | pmid = 15781101 | issue = 9464 | doi = 10.1016/S0140-6736(05)71142-9}}</ref><ref>{{cite journal | author = James C, Ugo V, Le Couedic JP, et al. | title = A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | journal = Nature | volume = 434 | issue = 7037 | pages = 1144–1148 | year = 2005 | pmid = 15793561 | doi = 10.1038/nature03546}}</ref><ref>{{cite journal | author = Levine RL, Wadleigh M, Cools J, et al. | title = Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | journal = Cancer Cell | volume = 7 | issue = 4 | pages = 387–397  | year = 2005 | pmid = 15837627 | doi = 10.1016/j.ccr.2005.03.023}}</ref><ref>{{cite journal | author = Kralovics R, Passamonti F, Buser AS, et al. | title = A gain-of-function mutation of JAK2 in myeloproliferative disorders | journal = N Engl J Med | volume = 352 | issue = 17 | pages = 1779–1790 | year = 2005 | pmid = 15858187 | doi = 10.1056/NEJMoa051113}}</ref><ref>{{cite journal | author = Campbell PJ, Scott LM, Buck G, et al. | title = Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study | journal = Lancet | volume = 366 | issue = 9501 | pages = 1945–1953 | year = 2005 | pmid = 16325696 | doi = 10.1016/S0140-6736(05)67785-9}}</ref>

==治疗==
现在临床实验的药物疗法未能提供一个有效的针对骨髓增生性疾病方法。现有针对原发性血小板增多症和红细胞增多症的办法是阻止急性出血综合症状；针对骨髓纤维化的方法包括有缓解[[贫血|贫血]]、[[脾肿大|脾肿大]]及其他症状。低剂量的[[阿司匹林|阿司匹林]]对原发性血小板增多症和红细胞增多症有效。酪氨酸激酶抑制剂则用于提高慢性粒细胞性白血病患者的控制预后<ref name=Tefferi2011/>。

近期一个JAK2抑制剂被批准用于原发性骨髓纤维化的治疗中<ref name=Tibes2012>{{cite journal |author=Tibes R, Bogenberger JM, Benson KL, Mesa RA |title=Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms |journal=Mol Diagn Ther |volume=16 |issue=5 |pages=269–83 |pmid=23023734 |doi=10.1007/s40291-012-0006-3|date=October 2012}}</ref>，此类抑制剂仍然尝试治疗其他骨髓增生性疾病。

[[脊骨神經醫學|脊骨神經醫學]] 也是一個可以幫助原发性骨髓纤维化的痛症治療 <ref>{{cite journal |vauthors=Eric Chu CP, |title=Chiropractic pain control in myelofibrosis: A case report|journal=New Horizons in Clinical Case Reports|year=2017|volume=2|page=7-9|doi=10.1016/j.nhccr.2017.08.001}}</ref>

==参考==
{{Reflist|2}}

== 外部链接 ==
* {{MeshName|Myeloproliferative+Disorders}}
* [https://web.archive.org/web/20130719094339/http://mpdinfo.org/ Myeloproliferative Disorders Website of The CMPD Education Foundation]
* [https://web.archive.org/web/20130521012201/http://mdip.co.uk/ Myeloproliferative Disorders in practice]
* [https://web.archive.org/web/20180902205516/http://www.mpd-rc.org/ Myeloproliferative Disorders Research Consortium]
* [http://www.cancer.gov/cancertopics/pdq/treatment/myeloproliferative/Patient/page1  MPN Info via Cancer.gov] {{Wayback|url=http://www.cancer.gov/cancertopics/pdq/treatment/myeloproliferative/Patient/page1 |date=20150409135658 }}
* [https://web.archive.org/web/20121128011209/http://www.spotlightonmpn.com/ Spotlight on MPN]

{{恶性髓系肿瘤}}

{{DEFAULTSORT:Myeloproliferative Disease}}
[[Category:白血病|Category:白血病]]